Newborn Screening

Labsystems Diagnostics' Neonatal Biotinidase kit is for enzymatic determination of biotinidase enzyme activity from blood samples dried on filter paper, with fluorometric detection, intended for newborn screening for biotinidase deficiency. Read More

Labsystems Diagnostics' Neonatal G6PD is an enzymatic method for the quantitative determination of glucose-6-phosphate dehydrogenase activity in blood samples dried on filter paper, with fluorometric detection, intended for newborn screening of glucose-6-phosphate dehydrogenase deficiency. Read More

Labsystems Diagnostics' Neonatal Galactose is a quantitative fluorometric test for the total galactose from dried blood spot samples. The test is based on the combined determination of free and galactose liberated from the cleavage of the galactose-1-phosphate. Read More

Labsystems Diagnostics' Neonatal Phenylalanine is a chemical method, with fluorometric detection, for quantitative determination of phenylalanine from blood specimens dried on filter paper, intended for newborn screening for phenylketonuria (PKU). Read More

Labsystems Diagnostics' Neonatal 17-OH-Progesterone FEIA test is a fluorometric enzyme immunoassay enabling the quantification of 17-hydroxyprogestrone steroid present in blood samples dried on filter paper. The test can be used for the screening of newborn for Congenital Adrenal Hyperplasia (CAH). Read More

Labsystems Diagnostics' Neonatal hTSH FEIA Plus is a  fluorometric enzyme immunoassay for the quantitative determination of human thyroid stimulating hormone (hTSH, human thyrotropin) in blood samples dried on filter paper as a primary test for screening of babies for congenital hypothyroidism (CH). Read More

Labsystems Diagnostics' Neonatal IRT FEIA is a fluorometric enzyme immunoassay for the quantitative determination of human immuno reactive trypsinogen (IRT) from blood samples dried on filter paper as a primary test for screening of babies for cystic fibrosis (CF). Read More

Labsystems Diagnostics' Neonatal Toxoplasma gondii IgM FEIA is a fluorometric enzyme immunoassay intended for the determination of IgM-class antibodies to Toxoplasma gondii in blood samples dried on filter paper. The test is intended as a primary method for screening newborns for congenital toxoplasmosis (CT). Read More

DBS Puncher Read More

Compact benchtop thermoshaker for carrying out controlled bioassay Read More

REVOLUTIONARY NS2400 NEONATAL SCREENING AUTOMATE With 25 plate capacity, 10 Assays on board, NS2400 automates the highest throughput sites or can handle the highest workload with extremely flexible, could be customized to your needs Read More

Multi-mode fluorescence microplate readers for high throughput bioassays. Read More

A versatile tool for Newborn Screening with high format flexibility and detection sensibility. Read More

Reliable Newborn Screening devices provided by Labsystems Diagnostics. Read More

Benchtop instruments for automated washing of 96-well microplates Read More

2nd tier LC-MS/MS Kit for Congenital Adrenal Hyperplasia.Congenital adrenal hyperplasia (CAH) refers to a group of autosomal recessive disorders that impair cortisol biosynthesis. CAH represents a continuous phenotypic spectrum with over 95% of all cases caused by 21-hydroxylase deficiency. CAH owing to 21-hydroxylase deficiency is the most common cause of genital ambiguity in the newborn and is present in about 1 in 15,000 live births worldwide Read More

Expanded NBS Panel Read More

Congenital Adrenal Hyperplasia (CAH) includes a group of disorders in which the cortisol production by adrenals is lowered. Cortisol is a steroid hormone necessary to maintenance of blood sugar level, partial maintenance of body fluids and electrolytes and protection of the body against stress. CAH cannot be cured, but it can be effectively treated by steroid substitution therapy if detected in early stage of life and disease course. Because of large individual variation in cortisol secretion, it is also important to monitor treatment very carefully. The means to determine an appropriate replacement dose includes measurement of serum/plasma17-hydroxyprogesterone. Labsystems Diagnostics' Neoscreen 17-OH-Progesterone FEIA test allows quantification of 17-hydroxyprogesterone in dried blood spot samples. Read More

Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency is the most common human enzyme deficiency; an estimated 400 million people worldwide are affected by this enzymopathy (6). With regards to the demographics of G6PD deficiency, most of the affected individuals reside in Africa, the Middle East, and Southeast Asia. The G6PD enzyme catalyzes an oxidation/reduction reaction. The G6PD enzyme functions in catalyzing the oxidation of glucose - 6 - phosphateto 6 - phosphogluconolactone while concomitantly reducing nicotinamide adenine dinucleotide phosphate (NADP+ ) to NADPH. This is the first step in the pentose phosphate pathway and is essential for the synthesis of both DNA and RNA (7). G6PD is also responsible for maintaining adequate levels of NADPH inside he cell. Read More

Galactosemia is an inherited metabolic abnormality comprising three distinctive clinical entities of the galactose pathway defects. Classic galactosemia is due to -Dgalactose- 1-phosphate-uridyl-transferase (GALT) defect (1). The test principle is based on extraction of Galactose & Galactose-1-phosphate from dried blood spot followed by enzymatic conversion of Galactose-1-phosphate & Galactose. Two kinds of extraction methods (acidic and heat) can be used for extraction step. After extraction Galactose-1-phosphate converts to Galactose in a reaction catalyst by alkaline phophatase enzyme Then this Galactose & extracted Galactose from dried blood spot converts to Galactonolactone by Galactose Dehydrogenasis & NAD coenzyme. The resulted NADH reduces Tetrazolium salt indicator dye from yellow to pink or red color. The figure demonstrates the reaction cycles. Final color change is used for colorimetric measurement (490 nm ) spectrophotometrically. Read More

Cystic Fibrosis (CF) is an autosomal recessive disorder affecting the lungs, pancreas, intestine and liver. CF is the most common in Caucasians with an incidence rate 1:2500 newborns. CF is caused by mutation in the gene for the protein cystic fibrosis transmembrane conductance regulator (CTFR) [1,2]. Large-scale neonatal screening for CF is performed by indentification of increased levels of immunoreactive trypsinogen (IRT) in blood. Diagnosis of CF is suggested by manifestations of chronic sinopulmonary disease and exocrine pancreatic insufficiency, confirmed by a sweat test. Neoscreen IRT EIA is a solid phase Enzyme immunoassay in which IRT is eluted from dried blood disks. It simultaneously forms a sandwich between the solid phase, coated with an antibody that recognizes Trypsinogen-1 (IRT-1) and excess of conjugate and unbound hIRT is washed away after incubation and the enzymatic reaction with Chromogenic substrate solution ( 3,3',5,5'-Tetramethylbenzidine (TMB) is performed. Read More

Congenital hypothyroidism (CH) is an endocrine disorder of newborns characterized by the decreased levels of thyroid hormones: thyroxine (T4) and triiodothyronine (T3) in periferal blood. In early perinatal period manifestations of CH are often non-specific, subtle or even non-existent [1-2]. However, the disease, if undiagnosed and untreated, leads to severe mental retardation, as well as to growth and developmental disturbances. Read More